An abstract is not available for this content so a preview has been provided. As you have access to content, full PDF via the ‘Save PDF’ action button.

An abstract is not available for this content so a preview has been provided. As you have access to content, full PDF via the ‘Save PDF’ action button.

An abstract is not available for this content so a preview has been provided. As you have access to content, full PDF via the ‘Save PDF’ action button.

An abstract is not available for this content so a preview has been provided. As you have access to content, full PDF via the ‘Save PDF’ action button.

An abstract is not available for this content so a preview has been provided. As you have access to content, full PDF via the ‘Save PDF’ action button.

An abstract is not available for this content so a preview has been provided. As you have access to content, full PDF via the ‘Save PDF’ action button.

The percentage of pts switching from 1st gen TKI in line to 3rd 2nd seems be low with 30% and it is questionable whether these data represent real world treatments. Therefore, we investigated the treatment pattern especially attrition rate between therapy EGFR mt+ pts. 965/1536 (63%) non-squamous NSCLC IV were tested for mt+. 148/965 (15%) an identified. To calculate PFS OS used Kaplan Meier lo...